Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442660 | 1.00 | LMNA (0.51) | LMNAHTR4ALDH1A1CYP2D6MEN1 | |
| SCHEMBL3471214 | 0.90 | LMNA (0.56) | LMNAHTR4ALDH1A1CYP2D6MEN1 | |
| SCHEMBL3711173 | 0.90 | LMNA (0.56) | LMNAHTR4ALDH1A1CYP2D6MEN1 | |
| SCHEMBL6336768 | 0.89 | HTR4 (0.62) | HTR4ALDH1A1CYP2D6MEN1KMT2A | |
| SCHEMBL13503072 | 0.88 | POLB (0.50) | ALDH1A1POLBKDM4ESMN1; SMN2RAD52 | |
| SCHEMBL362445 | 0.87 | LMNA (0.55) | LMNAHTR4ALDH1A1CYP2D6MEN1 | |
| SCHEMBL5502433 | 0.87 | LMNA (0.55) | LMNAHTR4ALDH1A1CYP2D6MEN1 | |
| SCHEMBL3284976 | 0.87 | LMNA (0.55) | LMNAHTR4ALDH1A1CYP2D6MEN1 | |
| SCHEMBL3527664 | 0.84 | ALDH1A1 (0.57) | LMNAALDH1A1CYP2D6MEN1KMT2A | |
| SCHEMBL3709691 | 0.84 | ALDH1A1 (0.57) | LMNAALDH1A1CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367824-B2 | Reacting anthranilic acid with formic acid compound in presence of a catalyst and solvent | UBE INDUSTRIES LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-7709479-B1 | Quinazoline derivatives and their use as pharmaceuticals | ASTRAZENECA (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1218354-B1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009103719-A1 | SUBSTITUTED 4-(INDOL-3-YL)QUINAZOLINES AND USE AND PRODUCTION THEREOF | FREIE UNIVERSITÄT BERLIN (DE) | 2009-08-27 | — | — | WO | disclosed |
| EP-1477481-B1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | UBE INDUSTRIES (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-7235559-B1 | Therapeutic quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-7105669-B1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-09-12 | — | — | US | disclosed |
| US-7081461-B1 | Quinazoline compounds and pharmaceutical compositions containing them | ASTRAZENECA AB (SE) | 2006-07-25 | — | — | US | disclosed |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | UBE INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1218357-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-04-06 | — | — | EP | disclosed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | disclosed |
| EP-1218355-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1218356-A1 | QUINAZOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1218357-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1218354-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021597-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001021596-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001021594-A1 | QUINAZOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001021595-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | NQO2, SDHA, CYP3A4 | LMNA 3978/4885HTR4 658/4885ALDH1A1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.